Schizophrenia Clinical Trial
Official title:
Influence of Nicotine on Cognitive Function in Schizophrenic Patients With and Without Comorbid Drug Dependence
Verified date | January 22, 2013 |
Source | National Institutes of Health Clinical Center (CC) |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Background:
- Individuals with schizophrenia have a significantly higher tendency to develop substance
abuse or dependence than the general population. For instance, people with schizophrenia
smoke much more than the general population, and many are dependent on street drugs such
as cocaine and heroin. However, these individuals are rarely included in research
studies that might provide more information about treatments for both schizophrenia and
substance abuse.
- Strong evidence suggests that schizophrenia and substance dependence have similar
effects on the brain, affecting attention, memory, and eye movement. Other research
indicates that schizophrenia and substance dependence affect the same parts of the
dopamine system, contributing to problems in brain function that require treatment.
These new developments provide a strong rationale to study the combination of
schizophrenia and substance dependence.
- Nicotine may help improve brain function and thinking in individuals with both
schizophrenia and drug dependence. Some of the thinking and memory problems experienced
by these individuals can be treated with nicotine. However, more research is needed to
determine exactly how nicotine affects individuals with both schizophrenia and drug
dependence.
Objectives:
- To determine whether individuals with schizophrenia and drug dependence show impairment
in tests of eye tracking, attention, and memory compared with healthy control subjects.
- To evaluate the effect of nicotine on eye tracking, attention, and memory in individuals
with both schizophrenia and substance dependence.
Eligibility:
- Current smokers (at least 10 cigarettes per day for the past year) between 18 and 55 years
of age who (1) have been diagnosed with schizophrenia/schizoaffective disorder, (2) have been
diagnosed with schizophrenia/schizoaffective disorder and are currently using heroin and/or
cocaine, or (3) are healthy individuals with no family history of psychotic illness.
Design:
- The study will consist of one training session and three testing sessions. Each session
will last about 2 hours.
- The training session will introduce participants to the study tests and evaluate their
tolerance of the nicotine nasal spray used in the study. Participants who cannot
tolerate the higher dose of the spray will not continue in the study.
- At the start of each testing session, smokers will have one cigarette to standardize the
time of the most recent exposure to nicotine.
- During the testing sessions, participants will receive a placebo spray, a lower dose of
nicotine, or a higher dose of nicotine, and then will be asked to perform tests that
evaluate attention, memory, and other thinking tasks.
Status | Completed |
Enrollment | 82 |
Est. completion date | January 22, 2013 |
Est. primary completion date | |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 60 Years |
Eligibility |
- INCLUSION CRITERIA: All participants must meet the following criteria: - age 18 60 - smoke 10 or more cigarettes/day for at least the past year Experimental groups 1 and 2, additional criteria: -DSM-IV diagnosis of schizophrenia or schizoaffective disorder (assessments pertaining to these diagnoses will be done in other MPRC screening protocols). Experimental group 2, additional criteria: -DSM-IV diagnosis of abuse or dependence on cocaine and/or heroin or on methadone or buprenorphine maintenance. EXCLUSION CRITERIA: Comprehensive medical history: -Exclusions: Heart disease, uncontrolled blood pressure (persistent systolic above 155 or diastolic above 95), neurological conditions (stroke, seizure, history of head injury), asthma, emphysema, chronic bronchitis, chronic obstructive pulmonary disease, pathology of nasal passages that precludes the effective administration of nicotine nasal spray. Drug Use Survey All subjects: - Exclude if treatment for tobacco dependence during the previous 6 months. - Healthy controls and schizophrenic patients without comorbid drug abuse or dependence: Exclude if history alcohol or other substance dependence ever, or alcohol or other substance abuse in the past year. Verify abstinence from controlled substances with urine screen (Iscreen). Participants in the above 2 groups who are positive for any illicit drug (with the exception of marijuana) will be excluded. Structured Clinical Interview for DSM-IV -Healthy controls: exclude if any current psychiatric disorder Urine pregnancy for females: -Exclude if positive. |
Country | Name | City | State |
---|---|---|---|
United States | National Institute on Drug Abuse, Biomedical Research Center (BRC) | Baltimore | Maryland |
United States | Matthews Media Group | Rockville | Maryland |
Lead Sponsor | Collaborator |
---|---|
National Institute on Drug Abuse (NIDA) | University of Maryland, College Park |
United States,
Avila MT, Sherr JD, Hong E, Myers CS, Thaker GK. Effects of nicotine on leading saccades during smooth pursuit eye movements in smokers and nonsmokers with schizophrenia. Neuropsychopharmacology. 2003 Dec;28(12):2184-91. — View Citation
Bennett ME, Bellack AS, Gearon JS. Treating substance abuse in schizophrenia. An initial report. J Subst Abuse Treat. 2001 Mar;20(2):163-75. — View Citation
Berman SM, Martinez RA, Noble EP. Familial alcoholism and ERPs: differences in probability sensitivity? Alcohol Alcohol. 1993 Nov;28(6):695-707. — View Citation
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05039489 -
A Study on the Brain Mechanism of cTBS in Improving Medication-resistant Auditory Hallucinations in Schizophrenia
|
N/A | |
Completed |
NCT05111548 -
Brain Stimulation and Cognitive Training - Efficacy
|
N/A | |
Completed |
NCT05321602 -
Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder
|
Phase 1 | |
Completed |
NCT04503954 -
Efficacy of Chronic Disease Self-management Program in People With Schizophrenia
|
N/A | |
Completed |
NCT02831231 -
Pilot Study Comparing Effects of Xanomeline Alone to Xanomeline Plus Trospium
|
Phase 1 | |
Completed |
NCT05517460 -
The Efficacy of Auricular Acupressure on Improving Constipation Among Residents in Community Rehabilitation Center
|
N/A | |
Completed |
NCT03652974 -
Disturbance of Plasma Cytokine Parameters in Clozapine-Resistant Treatment-Refractory Schizophrenia (CTRS) and Their Association With Combination Therapy
|
Phase 4 | |
Recruiting |
NCT04012684 -
rTMS on Mismatch Negativity of Schizophrenia
|
N/A | |
Recruiting |
NCT04481217 -
Cognitive Factors Mediating the Relationship Between Childhood Trauma and Auditory Hallucinations in Schizophrenia
|
N/A | |
Completed |
NCT00212784 -
Efficacy and Safety of Asenapine Using an Active Control in Subjects With Schizophrenia or Schizoaffective Disorder (25517)(P05935)
|
Phase 3 | |
Completed |
NCT04092686 -
A Clinical Trial That Will Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia
|
Phase 3 | |
Completed |
NCT01914393 -
Pediatric Open-Label Extension Study
|
Phase 3 | |
Recruiting |
NCT03790345 -
Vitamin B6 and B12 in the Treatment of Movement Disorders Induced by Antipsychotics
|
Phase 2/Phase 3 | |
Recruiting |
NCT05956327 -
Insight Into Hippocampal Neuroplasticity in Schizophrenia by Investigating Molecular Pathways During Physical Training
|
N/A | |
Terminated |
NCT03209778 -
Involuntary Memories Investigation in Schizophrenia
|
N/A | |
Terminated |
NCT03261817 -
A Controlled Study With Remote Web-based Adapted Physical Activity (e-APA) in Psychotic Disorders
|
N/A | |
Completed |
NCT02905604 -
Magnetic Stimulation of the Brain in Schizophrenia or Depression
|
N/A | |
Recruiting |
NCT05542212 -
Intra-cortical Inhibition and Cognitive Deficits in Schizophrenia
|
N/A | |
Completed |
NCT04411979 -
Effects of 12 Weeks Walking on Cognitive Function in Schizophrenia
|
N/A | |
Terminated |
NCT03220438 -
TMS Enhancement of Visual Plasticity in Schizophrenia
|
N/A |